Luis Borges Email and Phone Number
Houston, TX, US
Luis Borges's Location
Houston, Texas, United States, United States
Luis Borges's Contact Details
Luis Borges work email
- Valid
- Valid
- Valid
- Valid
- Valid
Luis Borges personal email
n/a
Luis Borges phone numbers
About Luis Borges
Luis Borges is a Chief Scientific Officer at Shinobi Therapeutics. He possess expertise in immunology, biotechnology, drug discovery, drug development, oncology and 23 more skills.
Luis Borges's Current Company Details
Shinobi Therapeutics
View
Chief Scientific Officer
Houston, TX, US
- Website:
- shinobitx.com
- Employees:
- 37
Luis Borges Work Experience Details
-
Chief Scientific OfficerShinobi TherapeuticsHouston, Tx, Us
-
Experienced Chief Scientific Officer Seeking New Opportunities In BiotechnologySelf-Employed Jul 2024 - PresentI wanted to share that, as of yesterday, I have parted ways with Metagenomi by mutual agreement. My time at Metagenomi has been incredibly valuable, and I am grateful for the opportunities and growth I’ve experienced, particularly in learning about gene editing technologies and therapies for genetic disorders.I am now looking forward to new challenges and opportunities, especially in the areas of Oncology, Hematology, and Immunology, where I have spent most of my industry career. If you know of any roles or have any suggestions, please feel free to reach out to me.Thank you to everyone who has supported me on this journey. I am excited about what the future holds and remain committed to developing novel therapies for grievous illnesses.
-
Chief Scientific OfficerMetagenomi Aug 2023 - Jul 2024Emeryville, California, Us• At Metagenomi, I oversaw the Research organization, leading the development of innovative gene editing tools and product candidates for the treatment of genetic disorders (in vivo gene editing) and autoimmune disorders (ex vivo edited CAR T cells).• I led a team of over 140 researchers working on multiple projects, including:1. Discovery and characterization of novel CRISPR-based systems for gene editing (CRISPR nucleases, Base editors, Prime editors, and large integration CAST and RNA-based systems).2. Development of analytical tools for off-target and specificity analysis.3. Development of gene therapies for conditions such as hemophilia A, TTR, AGT, and other genetic disorders.4. Development of autologous and allogeneic CAR T cell therapies for autoimmunity.• I unified all groups working on various aspects of discovery and drug development (Pre-Clinical, Cell Therapy, Discovery, Specificity and Off-Target analysis) under one organization to enhance coordination and productivity. I implemented a matrix organization to facilitate resource mobility and improve efficiency.• I restructured and refocused the Cell Therapy organization to enable product development from discovery to the clinic and pivoted into autoimmunity to address unmet medical needs in large patient populations. -
Chief Scientific Officer At Century TherapeuticsCentury Therapeutics Apr 2019 - Jul 2023Philadelphia, Pennsylvania, Us- Experience leading the development of iPSC-derived cancer cell therapies. At Century, we reprogram somatic cells to generate iPSC lines and differentiate the iPSCs in different immune cell types (current focus in on NK, alpha beta T cells, and gamma delta T cells). We use CRIPR-mediated gene editing to engineer the cells with multiple genetic features that enhance persistence, safety, homing to tumor sites, and tumor cell killing - Experience growing a start-up company and taking it public. When I joined the Century, there were about 15 people and 7-8 people in Research. In about 3.5 years, I lead the buildup of the Research organization to a multi-functional team of more than 100 people spread across three sites (Philadelphia, Seattle, and Hamilton, Canada). Our Research group is split into seven major groups: Gene editing, Protein Sciences, iPSC Biology, Immunology, In vitro and In vivo Pharmacology, Advanced Technologies, and GBM research- Experience fundraising with VC firms and equity investors through multiple rounds of investment. In March 2021, we closed a cross-over round where we raised $160 million. - Experience taking the company public. Immediately after we closed the cross-over round, we started working on the IPO. In less than 4 months and working through virtual meetings with the IPO team, we drafted and filed the S-1 form and went public in June of 2021 raising $242.7 million- Experience with BD opportunities and conducting due diligence activities. In January of 2022, we entered a major collaboration with BMS to develop and commercialize up to four iPSC-derived, engineered NK or T cell programs for hematologic malignancies and solid tumors. Century received $150M in cash ($100M upfront payment and $50M equity investment), with potential for additional $3B in payments plus royalties across multiple programs- Experience managing academic collaborations and SRAs - Experience with IND filings and direct interactions with the FDA -
Chief Scientific OfficerCell Medica Aug 2017 - Mar 2019Houston, Texas, UsLed a multifunctional research organization across multiple geographies: Houston (USA), London (UK), and Zurich (Switzerland).Directed collaboration with King's College in London, UK, to develop therapeutic TCRs for cell therapy targeting solid and liquid tumors.Spearheaded the development of autologous and allogeneic CAR-cell therapies in collaboration with Baylor College of Medicine, based on a novel cell therapy platform using CAR-NKT cells engineered with humanized CARs.Advanced cell therapy product candidates, including an autologous GD2-CAR NKT cell therapy for neuroblastoma, and two allogeneic NKT cell products: one targeting CD19 for B cell malignancies and another targeting GPC3 for hepatocellular carcinoma.- Experience leading and managing collaborations with academic institutions in the USA and overseas (UK)- Experience with BD opportunities and external diligence- Experience building a Research organization across multiple geographies: Houston (USA), London (UK), and Zurich (Switzerland)- Experience with IND filings - Experience fundraising with equity investors -
Svp ResearchFive Prime Therapeutics, Inc. Sep 2016 - Aug 2017• Transitioned the company from a platform-based enterprise to a drug development company focused on cancer immunotherapy. Restructured and expanded the R&D team to cover all aspects of drug development.• Built new groups, including the Immunology and Antibody Discovery & Protein Engineering teams, to develop multiple biologic agents aimed at blocking immune checkpoints, activating effector T cells, and inhibiting regulatory T cells. These agents included Fc-fusion proteins, multivalent activating VHH antibodies, checkpoint blockers, bi-specific T cell engagers, and ADCC-enhanced antibodies. • Discovered and advanced three drug candidates to IND-enabling studies, including a CD80-FC fusion protein (FPT155), a B7-H4 blocking antibody (FPT150), and a tetravalent anti-GITR antibody (FPA154). Two of these candidates, FPT155 and FPT150, successfully reached clinical trials.
-
Vp Immuno-Oncology ResearchFive Prime Therapeutics, Inc. Jul 2015 - Sep 2016
-
Executive DirectorFive Prime Therapeutics, Inc. Feb 2015 - Jun 2015
-
Senior DirectorFive Prime Therapeutics, Inc. May 2014 - Jan 2015
-
Scientific DirectorAmgen Nov 2011 - May 2014Thousand Oaks, Ca, UsLate in 2011, I transition from Oncology to the newly Therapeutic Innovation Unit to explore novel biology and approaches for cancer immunotherapy. My group was responsible for developing new approaches and agents for re-directed T cell killing and for investigating novel approaches to engage different immune cell subsets to control tumor growth. -
Scientific DirectorAmgen 2006 - 2011Thousand Oaks, Ca, Us• Developed next-generation BiTE antibodies for cancer treatment, utilizing Fc-based scaffolds to extend their half-life and efficacy. These new agents employed various scaffolds to combine the two binding domains, grafted onto an engineered Fc-region designed to enable the dimerization of two different chains, prevent ADCC, and manipulate pharmacokinetics.• The half-life extended (HLE) bi-specific engagers that Amgen is currently developing are based on one of the scaffolds created by my group.• Created bi-specific engagers that recruit not only T cells but also other immune cells, including NK cells and macrophages.
-
Scientific DirectorAmgen 2005 - 2006Thousand Oaks, Ca, Us• Developed novel agonistic antibodies targeting EpoR and led multiple biologics programs, including antibody-drug conjugates for ovarian cancer and ADCC-engineered antibodies for various malignancies.• Supported late-stage clinical candidates and approved biologics including Kepivance, Epogen, Aranesp, Neupogen, and Neulasta.• Supported the BLA filing for Kepivance in the US and Europe.
-
Principal ScientistAmgen 2004 - 2005Thousand Oaks, Ca, UsDepartment of Oncology and Hematology
-
Research ScientistAmgen 2003 - 2004Thousand Oaks, Ca, Us
-
ScientistImmunex 1999 - 2002Us• Developed cancer immunotherapies focused on enhancing dendritic and T-cell functions by using cytokines such as FLT3L and CD40L to stimulate the adaptive immune system.• Identified and characterized Leukocyte Immunoglobulin-like Receptors (LIRs, later renamed LILRs). -
Post-Doctoral ScientistImmunex 1996 - 1999Us
-
Post-Doctoral ScientistUniversity Of Washington 1995 - 1996Seattle, Wa, UsDepartment of Pathology, School of Medicine
Luis Borges Skills
Immunology
Biotechnology
Drug Discovery
Drug Development
Oncology
Antibodies
Life Sciences
Cell
Monoclonal Antibodies
Molecular Biology
Biopharmaceuticals
Inflammation
Immunoassays
Cell Culture
Cancer
Biomarkers
Assay Development
Biologics
In Vivo
Elisa
Hematology
Biomarker Discovery
Lifesciences
In Vitro
Animal Models
Toxicology
Cancer Research
Immunotherapy
Luis Borges Education Details
-
University Of Washington - School Of MedicineDepartment Of Pathology -
University Of LisbonMarine Biology
Frequently Asked Questions about Luis Borges
What company does Luis Borges work for?
Luis Borges works for Shinobi Therapeutics
What is Luis Borges's role at the current company?
Luis Borges's current role is Chief Scientific Officer.
What is Luis Borges's email address?
Luis Borges's email address is bo****@****gen.com
What is Luis Borges's direct phone number?
Luis Borges's direct phone number is +120643*****
What schools did Luis Borges attend?
Luis Borges attended University Of Washington - School Of Medicine, University Of Lisbon.
What are some of Luis Borges's interests?
Luis Borges has interest in Traveling, Running, Outdoor Activities, Scuba Diving.
What skills is Luis Borges known for?
Luis Borges has skills like Immunology, Biotechnology, Drug Discovery, Drug Development, Oncology, Antibodies, Life Sciences, Cell, Monoclonal Antibodies, Molecular Biology, Biopharmaceuticals, Inflammation.
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Aero Online
Your AI prospecting assistant
Select data to include:
Total price:
$0.00
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial